

Figure 1




Figure 2

Parameter	DS-6000a dose, mg/kg						Escalation Total (N=30)
	1.6 (N=1)	3.2 (N=6)	4.8 (N=6)	6.4 (N=8)	8.0 (N=6)	9.6 (N=3)	
Age, y, median (range)	63.0 (63-63)	59.5 (54-66)	71.0 (66-78)	65.5 (41-74)	64.0 (57-72)	59.0 (51-65)	64.5 (41-78)
Number of prior regimens, median (range)	8.0 (8-8)	3.5 (1-9)	4.5 (2-9)	2.5 (1-12)	2.5 (2-7)	6.0 (4-8)	3.0 (1-12)
Tumor types, n (%)							
ccRCC	0	2 (33.3)	2 (33.3)	3 (37.5)	1 (16.7)	0	8 (26.7)
Non-ccRCC	0	0	0	1 (12.5)	0	0	1 (3.3)
OVC	1 (100)	3 (50.0)	4 (66.7)	4 (50.0)	5 (83.3)	3 (100)	20 (66.7)
missing	0	1 (16.7)	0	0	0	0	1 (3.3)
ECOG PS, n (%)							
0	0	2 (33.3)	3 (50.0)	5 (62.5)	4 (66.7)	2 (66.7)	16 (53.3)
1	1 (100)	4 (66.7)	3 (50.0)	3 (37.5)	2 (33.3)	1 (33.3)	14 (46.7)

ECOG PS, eastern Cooperative Oncology Group performance status missing, tumor type was not entered at the data cut off.

Figure 3

TEAE, n (%)	N=30	
	All grades	Grade ≥3
Any TEAE	26 (86.7)	10 (33.3)
TEAE by preferred term (≥10% of patients)		
Fatigue	19 (63.3)	0
Nausea	18 (60.0)	0
Vomiting	14 (46.7)	0
Decreased appetite	12 (40.0)	0
Neutrophil count decreased	7 (23.3)	5 (16.7)
Diarrhoea	6 (20.0)	0
Dehydration	5 (16.7)	0
Hypokalaemia	5 (16.7)	3 (10.0)
Abdominal pain	4 (13.3)	0
Anaemia	4 (13.3)	3 (10.0)
Constipation	3 (10.0)	0
Cough	3 (10.0)	0
Headache	3 (10.0)	0
Muscular weakness	3 (10.0)	0
Sinus tachycardia	3 (10.0)	0
Urinary tract infection	3 (10.0)	0

Figure 4

TEAE, n (%)	N=30	
	All grades	Grade ≥3
Any related TEAE	25 (83.3)	7 (23.3)
Related TEAE by preferred term (≥10% of patients)		
Nausea	18 (60.0)	0
Fatigue	17 (56.7)	0
Vomiting	9 (30.0)	0
Neutrophil count decreased	7 (23.3)	5 (16.7)
Decreased appetite	6 (20.0)	1 (3.3)
Diarrhoea	4 (13.3)	0


Figure 5

Parameter	DS-6000a dose, mg/kg						Escalation total (N=24)
	1.6 (N=1)	3.2 (N=5)	4.8 (N=4)	6.4 (N=7)	8.0 (N=4)	9.6 (N=3)	
Best Single response, n (%)							
CR	0	0	0	0	0	0	0
PR	0	1 (20.0)	0	2 (28.6)	0	3 (100)	6 (25.0)
Non- CR/Non- PD	0	1 (20.0)	0	0	1 (25.0)	0	2 (8.3)
SD	0	3 (60.0)	3 (75.0)	3 (42.9)	3 (75.0)	0	12 (50.0)
PD	1 (100)	0	1 (25.0)	1 (14.3)	0	0	3 (12.5)
NE	0	0	0	1 (14.3)	0	0	1 (4.2)

Note: includes all subjects who received at least one dose of the study treatment and have completed at least one post-baseline tumor assessment or discontinued from treatment due to any reason prior to the first post-baseline tumor assessment.

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable

Figure 6



Note: Only subjects who received at least one dose of the study treatment and have completed at least one post-baseline tumor assessment are included.



Figure 7

Parameter	DS-6000a dose, mg/kg						Escalation total (N=17)
	1.6 (N=1)	3.2 (N=3)	4.8 (N=3)	6.4 (N=3)	8.0 (N=4)	9.6 (N=3)	
CA-125 response rate, n (%)							
Responder	0	1 (33.3)	2 (66.7)	2 (66.7)	2 (50.0)	1 (33.3.)	8 (47.1)

Note: Only subjects with measurable CA-125 at baseline and at least one post-baseline value are included.

Subjects can be evaluated for response only if they have a baseline sample that is $\geq 2 \times$ the upper limit of normal and within 2 weeks prior to starting treatment. CA-125 response is defined as at least a 50% reduction in CA-125 levels from a pre-treatment sample. The response must be confirmed and maintained for at least 28 days.

Figure 8



Note: Only subjects with measurable CA-125 at baseline and at least one post-baseline CA-125 value are included.

Figure 9

Case Summary: Patient With Clear Cell RCC

- 60-year-old man with stage IV RCC
- Treated with DS-6000a 3.2 mg/kg intravenously q3w
- 3 prior therapies
 - Sorafenib
 - Nivolumab
 - Telaglenastat + cabozantinib
- Cycle 18 treatment ongoing




Figure 10

Case Summary: Patient With Serous OVC

- 67-year-old woman with stage IV platinum-resistant OVC
- Treated with DS-6000a 6.4 mg/kg intravenously q3w
- 3 prior therapies
 - Paclitaxel + carboplatin with olaparib maintenance
 - Carboplatin + gemcitabine + bevacizumab
 - Pegylated liposomal doxorubicin
- Cycle 14 treatment ongoing





Figure 11



Notes: Only subjects with measurable disease at baseline and at least one post-baseline tumor scan are included in the waterfall graphs.

Figure 12




Figure 13


Parameter	DS-6000a dose, mg/kg						Total N=67
	1.6 (N=1)	3.2 (N=6)	4.8 (N=9)	6.4 (N=27)	8.0 (N=21)	9.6 (N=3)	
Age, y, median (range)	63.0 (63-63)	59.5 (54-66)	70.0 (54-78)	63.0 (41-83)	65.0 (34-77)	59.0 (51-65)	63.0 (34-83)
Number of prior regimens, median (range)	6.0 (5-6)	3.0 (1-9)	3.0 (1-9)	3.5 (1-12)	3.5 (1-13)	6.0 (4-8)	4.0 (1-13)
Tumortypes, n (%)							
ccRCC	0	2 (33.3)	2 (22.2)	5 (18.5)	4 (19.1)	0	13 (19.4)
Non-ccRCC	0	0	0	2 (7.4)	2 (9.5)	0	4 (6.0)
OVC	1 (100)	4 (66.7)	7 (77.8)	20 (74.1)	15 (71.4)	3 (100)	50 (74.6)
ECOG PS, n (%)							
0	0	2 (33.3)	5 (55.6)	10 (37.0)	5 (23.8)	2 (66.7)	24 (35.8)
1	1 (100)	4 (66.7)	4 (44.4)	17 (63.0)	16 (76.2)	1 (33.3)	43 (64.2)

Note: ECOG PS, eastern Cooperative Oncology Group performance status

Figure 14


	Study Total (N=67)	
	All Grades	Grade ≥3
Subjects with any TEAEs, n (%)	41 (61.2)	20 (29.9)
Nausea	39 (58.2)	0
Fatigue	33 (49.3)	4 (6.0)
Vomiting	27 (40.3)	1 (1.5)
Decreased appetite	22 (32.8)	2 (3.0)
Anaemia	21 (31.3)	15 (22.4)
Diarrhoea	18 (26.9)	1 (1.5)
Neutrophil count decreased	18 (26.9)	5 (7.5)
Dehydration	16 (23.9)	4 (6.0)
Platelet count decreased	12 (17.9)	0

Figure 15



Notes: Only subjects with measurable disease at baseline and at least one post-baseline tumor scan are included in the waterfall graphs.

Figure 16





Notes: Only subjects with measurable disease at baseline and at least one post-baseline tumor scan are included in the graphs.

Figure 17

Parameter	DS-6000a dose, mg/kg						Study Total (N=44)
	1.6 (N=1)	3.2 (N=4)	4.8 (N=7)	6.4 (N=15)	8.0 (N=14)	9.6 (N=3)	
Best Overall Response, n (%)							
Complete Response (CR)	0	0	1 (14.3)	0	0	0	1 (2.3)
Partial Response (PR)	0	0	3 (42.9)	5 (33.3)	4 (28.6)	2 (66.7)	14 (31.8)
Non-CR/Non-PD	0	1 (25.0)	1 (14.3)	0	1 (7.1)	0	3 (6.8)
Stable Disease (SD)	0	3 (75.0)	2 (28.6)	9 (60.0)	9 (64.3)	1 (33.3)	24 (54.5)
Progressive Disease (PD)	1 (100)	0	0	0	0	0	1 (2.3)
Not evaluable (NE)	0	0	0	1 (6.7)	0	0	1 (2.3)


Notes: includes all subjects who received at least one dose of the study treatment and have completed at least one post-baseline tumor assessment or discontinued from treatment due to any reason prior to the first post-baseline tumor assessment.

Figure 18



Note: Only subjects with measurable CA-125 at baseline and at least one post-baseline value are included in the graph.

Figure 19



Notes: Only subjects with measurable CA-125 at baseline and at least one post-baseline value are included in the waterfall graphs.

* Corresponds to subjects with baseline CA-125 $\geq 2 \times$ the upper limit of normal and within two weeks prior to starting treatment.

Figure 20

Parameter	DS-6000a dose, mg/kg						Total N=50
	1.6 (N=1)	3.2 (N=4)	4.8 (N=7)	6.4 (N=20)	8.0 (N=15)	9.6 (N=3)	
Median PFS, months (95% CI)	1.3 (NE)	13.9 (2.9-NE)	7.9 (3.7-NE)	5.8 (4.0-NE)	5.6 (3.2-8.3)	NE	5.8 (4.3-13.9)
PFS rate at 3 months, % (95% CI)	NE	66.7 (5.4-94.5)	100 (100-100)	100 (100-100)	84.6 (51.2-95.9)	100 (100-100)	88.6 (72.1-95.6)
PFS rate at 6 months, % (95% CI)	NE	66.7 (5.4-94.5)	83.3 (27.3-97.5)	28.6 (1.0-71.1)	25.4 (4.0-55.7)	100 (100-100)	47.0 (24.9-66.4)
PFS rate at 9 months, % (95% CI)	NE	66.7 (5.4-94.5)	41.7 (1.1-84.3)	28.6 (1.0-71.1)	12.7 (0.7-42.4)	100 (100-100)	35.3 (15.4-56.0)
PFS rate at 12 months, % (95% CI)	NE	66.7 (5.4-94.5)	41.7 (1.1-84.3)	28.6 (1.0-71.1)	NE	100 (100-100)	35.3 (15.4-56.0)

Notes: NE, Not evaluable; 95% CI, 95% confidence intervals

Figure 21

Parameter	DS-6000a dose, mg/kg						Total N=41
	1.6 (N=1)	3.2 (N=3)	4.8 (N=6)	6.4 (N=15)	8.0 (N=13)	9.6 (N=3)	
ORR, n (%)	0	0	4 (66.7)	5 (33.3)	4 (30.8)	2 (66.7)	15 (36.6)
95% CI	0.0-97.7	0.0-70.8	22.3-95.7	11.8-61.6	9.1-61.4	9.4-99.2	22.1-53.1

Notes: includes subjects with measurable disease at baseline who received at least one dose of the study treatment and have completed at least one post-baseline tumor assessment or discontinued from treatment due to any reason prior to the first post-baseline tumor assessment. 95% CI, 95% confidence intervals